Related Experiment Video

Updated: Aug 15, 2026

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells
09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

Gene therapy strategies for tumor antiangiogenesis

H L Kong1, R G Crystal

  • 1Division of Pulmonary and Critical Care Medicine, The New York Hospital-Cornell Medical Center, New York 10021, USA.

Journal of the National Cancer Institute
|March 5, 1998
PubMed

Insights

Gene transfer strategies offer a promising approach to deliver antiangiogenesis agents, inhibiting tumor growth by targeting new blood vessel generation. This method aims for sustained, localized delivery to minimize systemic toxicity for effective cancer treatment.

Area of Science:

  • Oncology
  • Gene Therapy
  • Molecular Biology

Background:

  • Solid tumor growth is dependent on angiogenesis (new blood vessel formation).
  • Antiangiogenesis agents are being investigated to inhibit tumor vascularization and growth.
  • Gene transfer offers a potential method for localized delivery of therapeutic proteins.

Purpose of the Study:

  • To review the concepts and potential of using gene transfer vectors for antiangiogenesis therapy.
  • To explore the feasibility of achieving high, sustained concentrations of antiangiogenic proteins within target organs.
  • To discuss the challenges and potential benefits of gene therapy for cancer treatment.

Main Methods:

  • Review of existing literature on antiangiogenesis and gene transfer strategies.
  • Conceptual framework for using gene transfer vectors to deliver antiangiogenic proteins.
  • Discussion of targeted organ delivery and local concentration effects.

Main Results:

  • Gene transfer can achieve sustained, high, local concentrations of antiangiogenic mediators.
  • Targeted delivery to tumor-containing organs can minimize systemic toxicity.
  • Potential for "genetic tourniquet" effect to suppress endothelial cell growth.

Conclusions:

  • Antiangiogenesis gene therapy holds promise for cancer treatment by inhibiting tumor vascularization.
  • Localized delivery via gene transfer can enhance efficacy and reduce side effects.
  • This approach may be most effective in early-stage cancers with low tumor burden.

More Related Videos

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells09:37

Defining Gene Functions in Tumorigenesis by Ex vivo Ablation of Floxed Alleles in Malignant Peripheral Nerve Sheath Tumor Cells

Published on: August 25, 2021

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis09:33

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.